World’s Top 20 Companies in Adrenocortical Carcinoma Treatment Market 2025: Industry Intelligence Report by Spherical Insights (2024–2035)
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, The Global Adrenocortical Carcinoma Treatment Market Size is projected to Grow from USD 3.91 Billion in 2024 to USD 7.62 Billion by 2035, at a CAGR of 6.25% during the forecast period 2025–2035. It is driven by its extreme rarity, aggressive biological nature, high recurrence rates, and substantial hormone production. These elements make management complicated, often necessitates a multidisciplinary team, and is best handled at high-volume specialized centers.
Introduction
The medical approaches used to control and treat adrenocortical carcinoma (ACC), an uncommon, aggressive cancer that starts in the adrenal glands, are referred to as adrenocortical carcinoma treatment. Pharmaceuticals, treatments, and surgical instruments intended for tumor excision and the management of advanced, metastatic, or recurrent disease make up the treatment market. Adrenocortical carcinoma (ACC) is a rare malignancy, with an incidence of about 0.5–2 cases per million people annually, translating to nearly 300–400 new cases each year in the United States, underscoring the niche yet critical demand within the Adrenocortical Carcinoma Treatment Market. In an effort to improve the currently dismal prognosis of advanced ACC, the industry is moving toward more individualized, targeted, and combination therapy, and specialized, high-growth, niche firms are starting to emerge. With the possible approval of novel treatments, such as combo treatments like EO2401 + Nivolumab, the market is anticipated to rise, combinations such as cabozantinib and cemiplimab are being tested in trials for locally advanced patients.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Adrenocortical Carcinoma Treatment Market.
Adrenocortical Carcinoma Treatment Market Size & Statistics
- The Market Size for Adrenocortical Carcinoma Treatment Was Estimated to be worth USD 3.91 Billion in 2024.
- The Market Size is Going to Expand at a CAGR of 6.25% between 2025 and 2035.
- The Global Adrenocortical Carcinoma Treatment Market Size is anticipated to reach USD 7.62 Billion by 2035.
- Asia Pacific is estimated to generate the highest demand during the forecast period in The Adrenocortical Carcinoma Treatment Market.
- North America is projected to grow the fastest during the forecast period in The Adrenocortical Carcinoma Treatment Market
Regional growth and demand
North America is expected to grow the fastest during the forecast period in the adrenocortical carcinoma treatment market. The rising prevalence of Adrenocortical Carcinoma in the United States and Canada, coupled with the increasing adoption of advanced diagnostic and therapeutic options, is driving market growth. In 2023, North America saw the introduction of over 50 new treatment programs and clinical initiatives to enhance early diagnosis and improve patient outcomes. Texas and California led regional adoption, primarily through specialized oncology centers implementing advanced surgical procedures, mitotane therapy, and targeted drug therapies. In May 2024, U.S. Food and Drug Administration accepted a Biologics License Application for subcutaneous Nivolumab (Opdivo), co-formulated with Halozyme’s rHuPH20, targeting multiple solid tumors and reflecting growing immunotherapy innovation across oncology treatment markets.
Asia Pacific is anticipated to generate the highest demand during the forecast period in the adrenocortical carcinoma treatment market. The region’s market growth is driven by the increasing prevalence of Adrenocortical Carcinoma, rising awareness of early diagnosis, and the expansion of specialized oncology centers in countries such as China, India, and Japan. The adoption of advanced treatment options, including mitotane therapy, targeted therapies, and minimally invasive surgical procedures, is improving patient outcomes and supporting market expansion.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Adrenocortical Carcinoma Treatment Market.
Top 10 trends in the Adrenocortical Carcinoma Treatment Market
- Rising Incidence and Market Growth
- Mitotane as Backbone Therapy
- Expansion of Immunotherapy
- Targeted Therapy Development
- Focus on Personalized Medicine
- Combination Strategies
- Advancements in Early Detection
- Increased R&D and Clinical Trials
- Strategic Collaborations
- Growth in Surgical Advancements
- Growing Incidence and Market Growth:
The 7MM (USA, EU4, UK, Japan, and China) is seeing an increase in incident instances, and the market is expected to expand at a notable CAGR between 2025 and 2034.
- Mitotane as Backbone Therapy:
Often used in conjunction with chemotherapy, mitotane (Lysodren) continues to be the cornerstone treatment for advanced and metastatic ACC.
- Immunotherapy Expansion:
New hope for metastatic disease is provided by the growing number of clinical studies for drugs like Dostarlimab, Pembrolizumab, and Nivolumab + Ipilimumab.
- Targeted Therapy Development:
New targeted therapies, such CY-101 and OR-449, are being developed with the goal of achieving more efficacy with fewer side effects.
- Emphasis on Personalized Medicine:
Tumor genetic and molecular profiling is being used more and more to customize and improve patient care.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the temporary power market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Adrenocortical Carcinoma Treatment Market.
Top 20 Companies Leading the Adrenocortical Carcinoma Treatment Market
- Bristol-Myers Squibb
- HRA Pharma
- Merck & Co.
- Exelixis
- Teva Pharmaceutical Industries
- Eli Lilly and Company
- Orphagen Pharmaceuticals
- Enterome SA
- Corcept Therapeutics
- Takeda Pharmaceutical
- Novartis AG
- Bayer AG
- AstraZeneca PLC
- Sanofi S.A.
- Genentech (Roche)
- GlaxoSmithKline
- Cytovation
- 3S Corporation
- Radionetics Oncology
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
Headquarter: New York, United States
Bristol-Myers Squibb is an American multinational pharmaceutical corporation founded in 1887. The company specializes in discovering, developing, and delivering innovative medicines for oncology, cardiovascular, immunology, and neuroscience. Bristol-Myers Squibb operates globally with more than 30,000 employees and reported revenue of approximately USD 52 Billion in 2025. The company invests heavily in research and development, with major R&D centers worldwide, including its global research facility in Princeton, New Jersey, focusing on cutting-edge therapies and advanced biopharmaceutical solutions.
- HRA Pharma
Headquarter: Paris, France
HRA Pharma is a French multinational pharmaceutical company founded in 1988. The company specializes in developing, manufacturing, and marketing innovative products in women’s health, emergency contraception, and hospital-based therapies. HRA Pharma operates globally with more than 1,200 employees and reported revenue of approximately USD 450 Million in 2025.
- Merck & Co.
Headquarter: Kenilworth, New Jersey, United States
Merck & Co., Inc. is an American multinational pharmaceutical corporation founded in 1891. The company specializes in developing prescription medicines, vaccines, biologic therapies, and animal health products. Merck operates globally with more than 74,000 employees and reported revenue of around USD 65 Billion in 2025. The company invests heavily in research and innovation, with major R&D centers worldwide, including the Merck Research Laboratories in Boston, Massachusetts, focusing on advancing treatments for oncology, infectious diseases, and chronic conditions through cutting-edge pharmaceutical and biotechnological solutions.
- Exelixis
Headquarter: Alameda, California, United States
Exelixis, Inc. is an American biotechnology company founded in 1994. The company specializes in discovering, developing, and commercializing small-molecule therapies for the treatment of cancer. Exelixis operates globally with over 2,000 employees and reported revenue of around USD 3.5 Billion in 2025. The company invests substantially in research and development, with key R&D facilities in Alameda and South San Francisco, focusing on innovative oncology therapeutics, targeted treatments, and combination therapies to improve patient outcomes in various cancer types.
- Teva Pharmaceutical Industries
Headquarter: Petah Tikva, Israel
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company founded in 1901. The company specializes in the development, manufacturing, and marketing of generic and specialty medicines across multiple therapeutic areas. Teva operates globally with over 50,000 employees and reported revenue of around USD 15 Billion in 2025.
Company Profiles
- Bristol-Myers Squibb
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- HRA Pharma
- Merck & Co.
- Exelixis
- Teva Pharmaceutical Industries
- Eli Lilly and Company
- Orphagen Pharmaceuticals
- Enterome SA
- Corcept Therapeutics
- Takeda Pharmaceutical
- Novartis AG
- Bayer AG
- AstraZeneca PLC
- Sanofi S.A.
- Genentech (Roche)
- GlaxoSmithKline
- Cytovation
- 3S Corporation
- Radionetics Oncology
- Millennium Pharmaceuticals
Our Reports
https://www.sphericalinsights.com/reports/russia-home-healthcare-devices-market
https://www.sphericalinsights.com/reports/australia-endoscopic-submucosal-dissection-market
Conclusion
The Global Adrenocortical Carcinoma (ACC) Treatment Market is poised for steady growth between 2025 and 2035, driven by the rarity and aggressive nature of ACC, coupled with the increasing focus on personalized and targeted therapies. North America is projected to grow the fastest, owing to the rising prevalence of ACC, advanced diagnostic infrastructure, and early adoption of innovative therapeutics, including immunotherapies and combination regimens. Asia Pacific is expected to generate the highest demand, supported by expanding oncology centers, heightened awareness of early diagnosis, and adoption of advanced treatment modalities.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Adrenocortical Carcinoma Treatment Market.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?